伊马替尼治疗慢性粒细胞白血病患者的临床疗效

Clinical effect of IM in the treatment of CML

目的探讨慢性粒细胞白血病(CML)患者采取伊马替尼治疗的疗效。方法选取92例于2011年5月~2012年5月期间我院接收的CML患者,分为加速期12例,慢性期65例,急变期15例,均给予伊马替尼治疗,观察治疗疗效。结果三组患者CHR、MCyR、CCy以及CMo R,以慢性期最高,急性期最低,组间比较差异均具统计学意义(P<0.05);各临床分期患者1、3、5年OS率、PFS率比较有明显差异性(P<0.05),其中以慢性期最高,其次为加速期、急变期。结论对于CML慢性期患者,伊马替尼治疗能使患者的生存时间延长,获得较高的细胞遗传学和血液学缓解率,但对于急变期和加速期患者疗效较差。

Objective To explore the clinical effect of IM （Imatinib） in the treatment of CML （chronic granulocytic leukemia）. Methods 92 CML patients treated from May 2011 to May 2012 in our hospital were selected. There were 12 accelerated cases, 65 chronic cases and 15 acute cases. IM was applied; the clinical effect was observed.Results The index of CHR, MCyR, CCy and CMoR for chronic cases was highest; the above index for acute cases was lowest（P 〈0.05）;within 1y, 3y and 5y, the index of OS and PFS for three staged cases was significantly different （P 〈0.05）; the index of OS and PFS for chronic cases was highest, followed by accelerated cases and acute cases. Conclusion For CML patients at chronic stage, IM can extend the patient’s survival time and improve the cell genetics and hematologic response rate. However, IM has a poorer effect in acute cases and accelerated cases.